Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note published on Wednesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

NASDAQ:EVOK opened at $3.68 on Wednesday. The firm’s fifty day moving average is $4.56 and its 200-day moving average is $4.72. Evoke Pharma has a 52 week low of $3.44 and a 52 week high of $12.32. The firm has a market cap of $5.47 million, a P/E ratio of -0.33 and a beta of 0.12.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent SEC filing.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.